CL2018002150A1 - Procedimientos para el tratamiento y la profilaxis de vih y sida. - Google Patents

Procedimientos para el tratamiento y la profilaxis de vih y sida.

Info

Publication number
CL2018002150A1
CL2018002150A1 CL2018002150A CL2018002150A CL2018002150A1 CL 2018002150 A1 CL2018002150 A1 CL 2018002150A1 CL 2018002150 A CL2018002150 A CL 2018002150A CL 2018002150 A CL2018002150 A CL 2018002150A CL 2018002150 A1 CL2018002150 A1 CL 2018002150A1
Authority
CL
Chile
Prior art keywords
aids
hiv
treatment
prophylaxis
procedures
Prior art date
Application number
CL2018002150A
Other languages
English (en)
Inventor
Daria Hazuda
Michael D Miller
Jay A Grobler
Deborah Anne Nicoll-Griffith
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2018002150A1 publication Critical patent/CL2018002150A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

PROCEDIMIENTO PARA INHIBIR LA TRANSCRIPTASA INVERSA DE VIH, EL TRATAMIENTO DE LA INFECCION POR VIH, EL TRATAMIENTO DE SIDA O ARC, EL RETRASO EN EL INICIO DE SIDA O ARC, O PARA LA PROFILAXIS DE LA INFECCION POR VIH, SIDA O ARC QUE COMPRENDE ADMINISTRAR 2’-DESOXI-4'-C-ETINIL-2-FLUOROADENOSINA) O UNA SAL O COCRISTAL DE ESTE.
CL2018002150A 2016-02-12 2018-08-08 Procedimientos para el tratamiento y la profilaxis de vih y sida. CL2018002150A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19

Publications (1)

Publication Number Publication Date
CL2018002150A1 true CL2018002150A1 (es) 2018-12-14

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002150A CL2018002150A1 (es) 2016-02-12 2018-08-08 Procedimientos para el tratamiento y la profilaxis de vih y sida.

Country Status (37)

Country Link
US (4) US10537589B2 (es)
EP (1) EP3413897B1 (es)
JP (4) JP6810972B2 (es)
KR (4) KR20220126787A (es)
CN (2) CN113509480A (es)
AU (3) AU2017217656B2 (es)
BR (1) BR112018016349A2 (es)
CA (1) CA3013473C (es)
CL (1) CL2018002150A1 (es)
DK (1) DK3413897T3 (es)
DO (1) DOP2018000183A (es)
EA (1) EA201891814A1 (es)
ES (1) ES2953535T3 (es)
FI (1) FI3413897T3 (es)
GE (2) GEP20217231B (es)
HR (1) HRP20230935T1 (es)
HU (1) HUE063532T2 (es)
IL (1) IL260874B2 (es)
JO (1) JOP20170038B1 (es)
LT (1) LT3413897T (es)
MD (1) MD3413897T2 (es)
MX (3) MX2022002925A (es)
MY (1) MY197090A (es)
NI (1) NI201800083A (es)
NZ (1) NZ745065A (es)
PH (1) PH12018501712A1 (es)
PL (1) PL3413897T3 (es)
PT (1) PT3413897T (es)
RS (1) RS64448B1 (es)
SG (1) SG11201806783WA (es)
SI (1) SI3413897T1 (es)
SV (1) SV2018005733A (es)
TN (1) TN2018000267A1 (es)
TW (2) TWI822652B (es)
UA (1) UA126375C2 (es)
WO (1) WO2017139519A1 (es)
ZA (1) ZA201805073B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN109893536B (zh) * 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用
EP3823632B1 (en) 2018-07-17 2025-10-29 Merck Sharp & Dohme LLC Efda in combination with doravirine for use in treating f227c mutated hiv infections
CA3122576C (en) * 2018-12-20 2025-11-25 Merck Sharp & Dohme Llc CRYSTALLINE FORMS OF THE NRTTI COMPOUND OF 4'-ETHYNYL-2-FLUORO-2'-DESOXYADENOSINE
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT831852E (pt) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
CN102174038A (zh) 2003-02-19 2011-09-07 耶鲁大学 用于治疗病毒感染的抗病毒核苷
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US8513205B2 (en) * 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MX391226B (es) 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ウイルス薬を送達するための薬物送達システム
WO2017222903A1 (en) * 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
AU2021268584A1 (en) * 2020-05-05 2022-12-01 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents and contraceptives
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
IL260874A (es) 2018-09-20
KR20210049201A (ko) 2021-05-04
US20200101098A1 (en) 2020-04-02
JP2021001189A (ja) 2021-01-07
MY197090A (en) 2023-05-24
JP2024001206A (ja) 2024-01-09
IL260874B2 (en) 2023-10-01
UA126375C2 (uk) 2022-09-28
JP6810972B2 (ja) 2021-01-13
AU2017217656A1 (en) 2018-08-23
KR20250136420A (ko) 2025-09-16
TW202417010A (zh) 2024-05-01
CN113509480A (zh) 2021-10-19
RS64448B1 (sr) 2023-09-29
FI3413897T3 (fi) 2023-08-25
EA201891814A1 (ru) 2019-01-31
HK1257347A1 (en) 2019-10-18
PL3413897T3 (pl) 2023-10-02
GEP20207190B (en) 2020-12-10
MX2022002924A (es) 2022-12-15
JP7559175B2 (ja) 2024-10-01
NZ784982A (en) 2025-03-28
AU2020202866B2 (en) 2022-04-07
ZA201805073B (en) 2019-05-29
TW201731514A (zh) 2017-09-16
DOP2018000183A (es) 2018-12-31
WO2017139519A1 (en) 2017-08-17
GEAP202014873A (en) 2020-07-27
HRP20230935T1 (hr) 2023-11-24
AU2022201686A1 (en) 2022-03-31
MX390604B (es) 2025-03-20
PT3413897T (pt) 2023-08-28
CA3013473A1 (en) 2017-08-17
CN108697727A (zh) 2018-10-23
AU2022201686B2 (en) 2024-08-08
US12171776B2 (en) 2024-12-24
JP7021314B2 (ja) 2022-02-16
MD3413897T2 (ro) 2023-11-30
KR102317570B1 (ko) 2021-10-25
TN2018000267A1 (en) 2020-01-16
MX2022002925A (es) 2023-02-10
JOP20170038B1 (ar) 2021-08-17
HUE063532T2 (hu) 2024-01-28
US20180055867A1 (en) 2018-03-01
JP7559175B6 (ja) 2024-10-22
BR112018016349A2 (pt) 2018-12-26
ES2953535T3 (es) 2023-11-14
SG11201806783WA (en) 2018-09-27
SV2018005733A (es) 2018-12-14
GEP20217231B (en) 2021-03-25
NI201800083A (es) 2018-10-05
EP3413897B1 (en) 2023-06-14
NZ745065A (en) 2023-11-24
AU2020202866A1 (en) 2020-05-21
PH12018501712A1 (en) 2019-05-15
JP2022062170A (ja) 2022-04-19
EP3413897A1 (en) 2018-12-19
CA3013473C (en) 2021-10-26
TWI911551B (zh) 2026-01-11
US11337991B2 (en) 2022-05-24
IL260874B1 (en) 2023-06-01
KR20180108815A (ko) 2018-10-04
SI3413897T1 (sl) 2023-11-30
MX2018009763A (es) 2018-11-29
US10537589B2 (en) 2020-01-21
US20220331350A1 (en) 2022-10-20
JP2019504857A (ja) 2019-02-21
LT3413897T (lt) 2023-08-25
DK3413897T3 (da) 2023-09-18
AU2017217656B2 (en) 2020-01-30
US20250073254A1 (en) 2025-03-06
KR20220126787A (ko) 2022-09-16
TWI822652B (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
CL2018002150A1 (es) Procedimientos para el tratamiento y la profilaxis de vih y sida.
AR130699A2 (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
CL2019000415A1 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih.
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
MX2019009443A (es) Metodos para tratar la influenza.
SV2018005629A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2017001209A1 (es) Inhibidor de cinasa aurora a
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
MX373703B (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
MX2018006264A (es) Capa intermedia para vidrio laminado, cuerpo de rollo y vidrio laminado.
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
CO2021007648A2 (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
PE20181088A1 (es) Mecanismo de resistencia a inhibidores de bromodominio bet
CR20110184A (es) Inhibidores de la integrasa del vih
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
MX2020000790A (es) Pautas para el tratamiento de infecciones por el vih y sida.
MX2021004215A (es) Combinaciones de inhibidores de la replicación del virus de la gripe.
MX2020000694A (es) Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih.
MX2018000384A (es) Composiciones para el tratamiento contra infecciones.
MX2019005700A (es) Metodos para tratar la osteocondromatosis multiple (mo).
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases